Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Jemielita

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Statistics in Medicine|May 15, 2023
Confounding adjustment in the analysis of augmented randomized controlled trial with hybrid control armLiang Li, Thomas Jemielita
Journal of Biopharmaceutical Statistics|January 20, 2025
Missing data in the eligibility criteria of synthetic controls from real-world dataLiang Li, Thomas Jemielita, Cong Chen
Statistics in Medicine|August 18, 2016
Improved power in crossover designs through linear combinations of baselinesThomas Jemielita, Mary Putt, Devan Mehrotra
Pharmaceutical Statistics|August 20, 2019
Oncology phase II proof-of-concept studies with multiple targets: Randomized controlled trial or single arm?Thomas Jemielita, Archie Tse, Cong Chen
Journal of Biopharmaceutical Statistics|December 23, 2021
Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation studyXi Wang, Leah Suttner, Thomas Jemielita, et al.
Clinical Pharmacology and Therapeutics|September 22, 2021
Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility StudyThomas Jemielita, Linnea Widman, Claire Fox, et al.
Statistics in Medicine|July 2, 2024
Exploratory subgroup identification in the heterogeneous Cox model: A relatively simple procedureLarry F León, Thomas Jemielita, Zifang Guo, et al.
JCO Clinical Cancer Informatics|January 13, 2021
Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World DataThomas Jemielita, Xiaoyun Nicole Li, Bilal Piperdi, et al.
JCO Clinical Cancer Informatics|August 20, 2021
Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With PembrolizumabThomas Jemielita, Xiaoyun Nicole Li, Thomas Burke, et al.
Pediatric Nephrology (Berlin, Germany)|March 2, 2017
Membrane pressures predict clotting of pediatric continuous renal replacement therapy circuitsAadil Kakajiwala, Thomas Jemielita, John Z Hughes, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Statistics in Medicine|May 15, 2023
Confounding adjustment in the analysis of augmented randomized controlled trial with hybrid control armLiang Li, Thomas Jemielita
Journal of Biopharmaceutical Statistics|January 20, 2025
Missing data in the eligibility criteria of synthetic controls from real-world dataLiang Li, Thomas Jemielita, Cong Chen
Statistics in Medicine|August 18, 2016
Improved power in crossover designs through linear combinations of baselinesThomas Jemielita, Mary Putt, Devan Mehrotra
Pharmaceutical Statistics|August 20, 2019
Oncology phase II proof-of-concept studies with multiple targets: Randomized controlled trial or single arm?Thomas Jemielita, Archie Tse, Cong Chen
Journal of Biopharmaceutical Statistics|December 23, 2021
Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation studyXi Wang, Leah Suttner, Thomas Jemielita, et al.
Clinical Pharmacology and Therapeutics|September 22, 2021
Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility StudyThomas Jemielita, Linnea Widman, Claire Fox, et al.
Statistics in Medicine|July 2, 2024
Exploratory subgroup identification in the heterogeneous Cox model: A relatively simple procedureLarry F León, Thomas Jemielita, Zifang Guo, et al.
JCO Clinical Cancer Informatics|January 13, 2021
Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World DataThomas Jemielita, Xiaoyun Nicole Li, Bilal Piperdi, et al.
JCO Clinical Cancer Informatics|August 20, 2021
Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With PembrolizumabThomas Jemielita, Xiaoyun Nicole Li, Thomas Burke, et al.
Pediatric Nephrology (Berlin, Germany)|March 2, 2017
Membrane pressures predict clotting of pediatric continuous renal replacement therapy circuitsAadil Kakajiwala, Thomas Jemielita, John Z Hughes, et al.
Pageof 4